Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Zhejiang Hisun Pharmaceutical Co., Ltd.
WARNING LETTER
•Zhejiang Hisun Pharmaceutical Co., Ltd.•March 7, 2015

Zhejiang Hisun Pharmaceutical Co., Ltd. – FDA Warning Letter, Mar 7, 2015

Record Details

The FDA issued a Warning Letter to Zhejiang Hisun Pharmaceutical Co., Ltd. on December 31, 2015, following an inspection from March 2-7, 2015. The inspection identified significant deviations from current Good Manufacturing Practice (CGMP) for active pharmaceutical ingredients (API), rendering their drugs adulterated under Section 501(a)(2)(B) of the FD&C Act.

Key violations include: 1. **Failure to prevent unauthorized data access/changes and ensure data integrity:** Investigators found systemic data manipulation, including routine re-testing without justification, deletion of analytical data, and disabled audit trails on HPLC systems. Examples cited include deleted HPLC data for validation stability batches and API batches, and missing raw data for customer complaints regarding subpotency and OOS impurity levels. The firm's responses regarding system suitability failures or training purposes for deleted data were deemed inadequate. 2. **Failure to conduct appropriate microbiological testing:** During the inspection, dried and cracked culture media plates were observed, compromising microbial testing. The firm's investigation was insufficient, failing to evaluate all associated batches or adequately address customer complaints of OOS microbial results.

Additionally, the firm delayed providing requested records during the inspection, which can lead to drugs being deemed adulterated under Section 501(j) of the FD&C Act.

Required corrective actions include a comprehensive investigation into data integrity deficiencies and root causes, a risk assessment

Company
Zhejiang Hisun Pharmaceutical Co., Ltd.
Inspection date
March 7, 2015
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Thomas J. Cosgrove
View Company Profile

ID · 1c80aaa0-7c21-48ef-8a73-80a5561a3e9f

Violation Codes5
21 U.S.C. 351(a)(2)(B)FD&C Act 501(a)(2)(B)FD&C Act 801(a)(3)21 U.S.C. 381(a)(3)21 U.S.C. 356C(a)(1)

Full citation text and observation details available on the Dashboard.

Other documents for Zhejiang Hisun Pharmaceutical Co., Ltd.
  • 483 - 2019-06-07June 7, 2019
  • 483 - 2017-08-11August 11, 2017
  • 483 - 2017-08-07August 7, 2017
  • 483 - 2017-01-19January 19, 2017
  • 483 - 2017-01-16January 16, 2017

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Zhejiang Hisun Pharmaceutical Co., Ltd.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.